Johns-Manville Corp & Philadelphia Asbestos Inc PACOR Asbestos Trust
Johns-Manville Corporation and Philadelphia Asbestos Company/PACOR have related asbestos-claim histories, but they should not be presented as one interchangeable trust. Johns-Manville liabilities are handled through the Manville Personal Injury Settlement Trust. PACOR had its own Settlement Trust and a court-approved relationship with Manville involving asbestos-containing Manville products distributed by PACOR. This page explains that distinction and uses current claims-administrator records, court records and filed financial information.
Johns-Manville and PACOR Trust Facts
| Johns-Manville debtor | Johns-Manville Corporation |
|---|---|
| Manville bankruptcy filing | 1982 |
| Manville Trust | Manville Personal Injury Settlement Trust |
| Manville Trust established | 1988 |
| Current Manville claims administrator | Claims Resolution Management Corporation (CRMC) |
| Current Manville pro rata payment percentage | 5.6%, effective September 2, 2026 |
| PACOR entity | Philadelphia Asbestos Company / PACOR, Inc. |
| PACOR role | Distributor of Johns-Manville asbestos-containing products in claims documented by federal courts |
| PACOR trust | PACOR Settlement Trust |
| Current electronic claims access | CRMC e-Claims lists both the Manville Personal Injury Settlement Trust and Pacor Trust |
Important: A PACOR distribution claim and a direct Manville claim can involve related product evidence, but the trust identities, claim records and procedures should remain distinct.
Johns-Manville Bankruptcy and Manville Trust
Johns-Manville entered Chapter 11 in 1982 under the weight of asbestos liabilities. The reorganization produced the Manville Personal Injury Settlement Trust, which became a landmark asbestos bankruptcy trust for present and future personal-injury claimants.
Federal appellate records describe a Trust Distribution Process that assigns values to asbestos-disease categories and pays claimants a pro rata share determined by the trust. The payment percentage is periodically reevaluated based on assets, liabilities and expected future claims.
Philadelphia Asbestos/PACOR Relationship
Federal court records identify Philadelphia Asbestos Company, trading as PACOR, as a distributor involved in litigation over asbestos manufactured by Johns-Manville. In one 1970s personal-injury action, PACOR impleaded Johns-Manville as the alleged manufacturer of the asbestos at issue.
PACOR later entered bankruptcy and established the PACOR Settlement Trust. Court records and PACOR claim materials show that certain PACOR claims were tied to Manville products distributed by PACOR. The PACOR proof-of-claim process has requested a Manville Trust claim number along with dates of exposure, worksite, employer and the principal Manville product.
This relationship is why a page covering both names can be useful, but it is also why the two claim paths must not be collapsed into a single “Johns-Manville/PACOR trust.”
Current Manville Payment Percentage
CRMC announced on September 3, 2026 that the Manville Trustees, with the required concurrence, approved an immediate increase in the Manville Trust’s pro rata payment percentage from 5.1% to 5.6%. CRMC implemented the 5.6% rate in e-Claims on September 2, 2026 for future offers and reissued outstanding offers at the new percentage.
The notice also states that claims eligible for retroactive supplemental payment adjustments were identified for planned payments in mid-October 2026. A new release is not required solely for that supplemental adjustment.
PACOR percentage: this page does not assign the Manville 5.6% rate to the PACOR Settlement Trust. PACOR payment terms must be verified under PACOR’s own current procedures.
Need help reviewing Johns-Manville or PACOR exposure records? Call 800.291.0963. Live chat available 24/7, 365 days a year. Submit Your Case.
Claim Values and Filing Evidence
The Manville Trust Distribution Process uses disease categories, liquidated claim values and a pro rata payment percentage. The current 5.6% rate is a percentage applied under that process; it is not itself a disease value and does not guarantee a particular payment.
Because the currently accessible primary records reviewed for this page did not provide a sufficiently clear current Manville disease-value table suitable for publication here, this page does not insert a mesothelioma or lung-cancer scheduled value from a secondary source.
For PACOR-related claims, product-distribution evidence can be especially important. Supporting information may include medical records, employment history, worksite and employer information, dates of exposure, product identification and records tying the asbestos-containing product to Manville and its distribution through PACOR.
Current Manville Financial Record
A court-filed Manville financial statement for the second quarter of 2026 reported approximately $570.5 million in net claimants’ equity as of June 30, 2026. This is a dated accounting measure from the filed financial statements and should not be described as a guaranteed pool available for any individual claimant.
The figure can change with investment performance, operating expenses, claim payments and other trust activity. For that reason, this page states the exact reporting date and does not convert the balance into an estimated per-claim recovery.
Confirmed Primary Sources for Trust Facts
Trust facts on this page are based on official claims-administrator materials, court-filed financial statements and federal court records rather than law-firm or lead-generation websites.
- Claims Resolution Management Corporation — Manville: September 3, 2026 notice increasing the pro rata payment percentage from 5.1% to 5.6% and describing September 2 e-Claims implementation.
- CRMC client and e-Claims records: current claims-processing listings for the Manville Personal Injury Settlement Trust and Pacor Trust.
- Manville Q2 2026 financial statements filed with the court: approximately $570.5 million in net claimants’ equity as of June 30, 2026.
- Federal appellate decisions concerning the Manville Trust: Trust Distribution Process, disease-category valuation and pro rata payment framework.
- Federal appellate PACOR litigation: Philadelphia Asbestos Company/PACOR’s distributor relationship with Johns-Manville asbestos products.
- PACOR official claim materials: Manville Trust claim number and PACOR/Manville exposure information requested for applicable PACOR claims.
Not published without adequate current primary confirmation: current Manville mesothelioma scheduled value, current lung-cancer scheduled value, PACOR payment percentage, cumulative Manville claims paid, cumulative PACOR claims paid or lifetime dollars paid by either trust.
Other Trust and Legal Options
A person exposed to Johns-Manville products may also have encountered asbestos products associated with other manufacturers, distributors, contractors or equipment companies. Each potential claim requires its own medical and exposure evidence and current procedural review.
Related Asbestos Trust Fund Resources
Johns-Manville, PACOR and Manufacturer Trust Information
- Philadelphia Asbestos Corporation PACOR Asbestos Trust
- Asbestos Manufacturer Trust Funds
- What Are Asbestos Trust Funds?
Filing and Eligibility
- Understanding Asbestos Trust Funds
- Step-by-Step Guide to Filing an Asbestos Trust Claim
- Asbestos Trust Fund Requirements
Payments and Legal Strategy
Johns-Manville and PACOR Asbestos Trust FAQs
Are Johns-Manville and PACOR the same asbestos trust?
No. Johns-Manville claims are handled through the Manville Personal Injury Settlement Trust. PACOR established the PACOR Settlement Trust and had a separate claim relationship involving Manville products it distributed.
What is the current Manville Trust payment percentage?
CRMC announced a 5.6% pro rata payment percentage, implemented in e-Claims on September 2, 2026.
What was the prior Manville payment percentage?
The prior rate was 5.1%. CRMC’s September 3, 2026 notice states that the Trustees approved an immediate increase to 5.6%.
Does the 5.6% Manville percentage apply automatically to PACOR claims?
No. The Manville rate should not be assigned to the PACOR Settlement Trust. PACOR payment rules must be verified under PACOR’s own procedures.
What was PACOR’s relationship to Johns-Manville?
Federal court records document PACOR as a distributor involved with Johns-Manville asbestos-containing products, and PACOR claim materials request information about Manville products distributed by PACOR.
How much did the Manville Trust report in net claimants’ equity in mid-2026?
The court-filed Q2 2026 financial statements reported approximately $570.5 million in net claimants’ equity as of June 30, 2026. This is a dated accounting figure, not an individual claim guarantee.
What evidence can support a Johns-Manville or PACOR claim?
Relevant evidence can include disease-specific medical documentation plus employment, worksite, employer, exposure-date and product information connecting the claimant to the applicable asbestos exposure.
Does CRMC currently process both Manville and PACOR claims?
CRMC’s current client and e-Claims materials list both the Manville Personal Injury Settlement Trust and Pacor Trust.
Get Help Reviewing a Johns-Manville or PACOR Asbestos Claim
If you or a family member has been diagnosed with mesothelioma, asbestos-related lung cancer or another asbestos-related disease and you are investigating Johns-Manville or PACOR exposure, a review can help organize medical records, employment history, worksites and product evidence.
Call 800.291.0963 to discuss the work history, products, worksites and years of possible exposure you remember. Live chat is available 24/7, 365 days a year. Submit Your Case using the form below.
Prior asbestos exposure does not automatically establish eligibility for a trust claim or lawsuit. Trust availability, eligibility, filing requirements, payment percentages and legal options depend on current procedures, evidence and individual circumstances. Compensation is not guaranteed.
⚕️ Legal & Medical Information Disclaimer
This page provides general educational information and is not medical or legal advice. The information does not establish asbestos exposure, diagnosis, causation, liability, claim eligibility or compensation. Medical concerns should be discussed with a qualified healthcare professional, and legal questions should be reviewed with a qualified attorney.